Monika Gad

Monika Gad

Auto-generated profile, based on publicly available information

Monika Gad

Department of Cellular Engineering & Disease Modeling, Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
CMCaroline B.K. Mathiesen
Caroline B.K. Mathiesen
ARAsha M. Rudjord-Levann
Asha M. Rudjord-Levann
MGMonika Gad
Monika Gad
JLJesper Larsen
Jesper Larsen
FSFinn Sellebjerg
Finn Sellebjerg
APAnders Elm Pedersen
Anders Elm Pedersen

26 October 2020 in Stem Cells International
Verified
Journal Article
Open access
PDF file
MJMorten Juhl
Morten Juhl
Bjarke FollinBjarke Follin
Bjarke Follin
MGMonika Gad
Monika Gad
JLJesper Larsen
Jesper Larsen
JKJens Kastrup
Jens Kastrup
AEAnnette Ekblond
Annette Ekblond
Allogeneic cell-based therapies using adipose tissue-derived stromal cells (ASCs) offer an off-the-shelf alternative to autologous therapy. An underlying assumption is that ASC can modulate the immune response of the recipient. However, in vitro models are required to explore and identify cell interactions and mechanisms of action, to ensure sufficient and sustained effects, and to document these. In this study, we shed light on the effect of ASC manufactured for clinical use on monocyte-derived dendritic cells and an inflammatory microenvironment. ASCs were isolated from healthy voluntary donors, expanded using a human platelet lysate in bioreactors, and cryopreserved as per clinical use. Monocyte-derived dendritic cells were generated by isolation of monocytes and differentiation with GM-CSF and IL-4. Dendritic cells were cocultured with different ratios of ASC and matured with LPS and IFN-γ. Dexamethasone was included as an immunosuppressive control. Dendritic cells were analyzed by flow cytometry for CD11c, CD40, CD80, CD83, CD86, PD-L1, and HLA-DR, and supernatants were analyzed for FGF2, HGF, IL-10, IL-12p70, LIF, MIF, PDGF, PlGF, and IDO. Reduced expression of maturation markers was observed on ASC-treated dendritic cells, while high levels of PD-L1 were maintained. Interestingly, the expression of CD83 was elevated. Escalating ratios of ASC did not affect the concentration of IL-10 considerably, whereas the presence of IL-12 was reduced in a dose-dependent manner. Besides offsetting the IL-12/IL-10 balance, the concentrations of IDO and MIF were elevated in cocultures. Concentrations of FGF2, HGF, LIF, and PIGF were high in ASC cocultures, whereas PDGF was depleted. In a robust coculture model, the addition of ASC to dendritic cells inhibited the dendritic maturation substantially, while inducing a less inflammatory and more tolerogenic milieu. Despite the exposure to dendritic cells and inflammatory stimuli, ASC resulted in supernatants with trophic factors relevant for regeneration. Thus, ASC can perform immunomodulation while providing a regenerative environment.

14 May 2025 in Experimental Cell Research
Verified
Journal Article
Open access
NMNatasha Madsen
Natasha Madsen
BNBoye Schnack Nielsen
Boye Schnack Nielsen
ISIsabella Skandorff
Isabella Skandorff
CRCarlos Rodriguez-Pardo
Carlos Rodriguez-Pardo
SHSine Reker Hadrup
Sine Reker Hadrup
MGMonika Gad
Monika Gad
Advanced 3D heterospheroids, composed of cancer, fibroblast, and immune cells, serve as more physiologically relevant models for anticancer drug screening and immunotherapy research compared to traditional 2D cultures. This study aimed to optimize the culturing, dissociation, and analysis of heterospheroids, addressing limitations that restrict their broader use in immunotherapy research. Our study revealed significant effects of Human Plasma-Like culture medium on cell viability, necrotic core formation, and the spatial organization of cancer and fibroblast cells within heterospheroids compared to DMEM and RPMI media. In HT-29 heterospheroids, cell viability decreased from 75% in DMEM to 20% in HPLM, which was accompanied by increased necrotic core formation and elevated PD-L1 expression. TrypLE™ effectively dissociated heterospheroids but compromised immune cell viability and surface marker detection. In comparison, Accutase™ significantly reduced cell yield, while collagenase I preserved immune cell markers but affected those on cancer cells. Furthermore, we developed a luciferase-based assay to measure immune-mediated cancer cell killing in heterospheroids, excluding signals from non-target cells, such as dying fibroblasts and immune cells, without requiring spheroid lysis or dissociation. Our findings highlight the importance of tailoring experimental conditions to reflect specific tumor characteristics, thus enhancing the utility of heterospheroids in drug discovery and immunotherapy research.

15 December 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
AEA. Elkhouly
A. Elkhouly
Rana A. YounessRana A. Youness
Rana A. Youness
MGM. Gad
M. Gad
Triple Negative Breast Cancer (TNBC) is the most belligerent subtype of BC. Yet, it is considered the best candidate for immunotherapy. As TNBC microenvironment is rich in CD8+ T lymphocytes (CTLs) and Natural Killer cells (NKs), the main key players in BC immune surveillance. During the antitumor immune-response, CTLs and NKs recognize and eliminate BC cells through an array of activating receptors expressed on their surface. CD226 and NKG2D are among the most vital activating receptors present on CTLs, NKs and NKT cells. The rate limiting step in tumor eradication is the binding of the aforementioned receptors to their respective ligands (Major histocompatibility complex class I chain-related proteins A and B (MICA/B) and CD155). Unfortunately, recent studies highlight the extensive shedding of MICA/B and CD155 in TNBC patients. Lately, our group nominated miR-486-5p as an immuno-activating miRNA. However, its impact on TNBC immune ligands has never been investigated. Therefore, our aim is to investigate the impact of miR-486-5p on MICA/B and CD155 in an attempt to alleviate the immune-suppressive nature of TNBC cells. TNBC patients (n = 25) were recruited. Bioinformatics were performed to verify the binding of miR-486-5p to MICA/B and CD155. MDA-MB-231 and MCF7 cells were cultured and transfected with miR-486-5p oligonucleotides. Total RNA was extracted and quantified by qRT-PCR. Cellular viability and clonogenicity were performed using MTT and colony forming assays, respectively. TNBC patients showed a significant down-regulatory pattern of miR-486-5p, MICA, MICB and CD155 compared to its normal counterparts. In a similar pattern, miR-486-5p, MICA, MICB and CD155 were found to be markedly down-regulated in MDA-MB-231 cells. In-silico results proved that miR-486-5p potentially targets MICA, MICB and CD155. Ectopic expression of miR-486-5p (>1000 folds) resulted in a marked induction of MICA/B (2 folds) and CD155 (5 folds) thus potentiating NKs and CTLs cytotoxicity. Functionally, miR-486-5p mimics resulted in a significant repression of TNBC cellular viability and colony forming ability. miR-486-5p is an immunomodulatory tumor suppressor miRNA acts by alleviating the immunesuppressive profile of TNBC cells. German University in Cairo. Has not received any funding. All authors have declared no conflicts of interest.